Business Insider1d
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...
Rani Therapeutics Holdings options imply 12.6% move in share price post-earnings
Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 12.6%, or 30c, after results ...
Nasdaq7d
Rani Therapeutics to Participate in Upcoming Investor Conferences
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...
Stockhouse29d
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company ...